Improving the quality of decision-making processes for prostate cancer screening: Progress and challenges
Menée entre 2007 et 2011 par questionnaires téléphoniques auprès de 1 893 hommes d'âge compris entre 45 et 70 ans, cette étude évalue l'efficacité de deux outils d'aide à la décision en matière de dépistage du cancer de la prostate
Guidelines recommend that patients be informed about potential benefits and harms from prostate cancer screening and that screening decisions involve a discussion between patients and their physicians. Despite this consensus, achieving high-quality decision-making processes in practice is difficult. Clinicians function in a time-constrained environment and know that ordering a prostate-specific antigen (PSA) blood test is simple, whereas ensuring that patients fully understand the potential ramifications of entering a screening program is far more difficult and time-consuming. Explaining such concepts as biopsy threshold, false-positive results, overdiagnosis, and uncertainty about magnitude of benefit is challenging and cannot be done quickly.
JAMA Internal Medicine , commentaire, 2012